Abstract
Priapism is an erectile disorder involving uncontrolled, prolonged penile erection without sexual purpose, which can lead to erectile dysfunction. Ischemic priapism, the most common of the variants, occurs with high prevalence in patients with sickle cell disease. Despite the potentially devastating complications of this condition, management of recurrent priapism episodes historically has commonly involved reactive treatments rather than preventative strategies. Recently, increasing elucidation of the complex molecular mechanisms underlying this disorder, principally involving dysregulation of nitric oxide signaling, has allowed for greater insights and exploration into potential therapeutic targets. In this review, we discuss the multiple molecular regulatory pathways implicated in the pathophysiology of priapism. We also identify the roles and mechanisms of molecular effectors in providing the basis for potential future therapies.
Keywords: Adenosine, nitric oxide, opiorphins, rho kinase, recurrent ischemic priapism treatment, testosterone.
Current Drug Targets
Title:Molecular Pathophysiology of Priapism: Emerging Targets
Volume: 16 Issue: 5
Author(s): Uzoma A. Anele, Belinda F. Morrison and Arthur L. Burnett
Affiliation:
Keywords: Adenosine, nitric oxide, opiorphins, rho kinase, recurrent ischemic priapism treatment, testosterone.
Abstract: Priapism is an erectile disorder involving uncontrolled, prolonged penile erection without sexual purpose, which can lead to erectile dysfunction. Ischemic priapism, the most common of the variants, occurs with high prevalence in patients with sickle cell disease. Despite the potentially devastating complications of this condition, management of recurrent priapism episodes historically has commonly involved reactive treatments rather than preventative strategies. Recently, increasing elucidation of the complex molecular mechanisms underlying this disorder, principally involving dysregulation of nitric oxide signaling, has allowed for greater insights and exploration into potential therapeutic targets. In this review, we discuss the multiple molecular regulatory pathways implicated in the pathophysiology of priapism. We also identify the roles and mechanisms of molecular effectors in providing the basis for potential future therapies.
Export Options
About this article
Cite this article as:
Anele A. Uzoma, Morrison F. Belinda and Burnett L. Arthur, Molecular Pathophysiology of Priapism: Emerging Targets, Current Drug Targets 2015; 16 (5) . https://dx.doi.org/10.2174/1389450115666141111111842
DOI https://dx.doi.org/10.2174/1389450115666141111111842 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology Gene Therapy for Heart Transplantation-Associated Acute Rejection, Ischemia / Reperfusion Injury and Coronary Arteriosclerosis
Current Gene Therapy The Woman’s Heart: Insights into New Potential Targeted Therapy
Current Medicinal Chemistry Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Current Pharmaceutical Design Possibility of Enhanced Risk of Retinal Angiogenesis in Athletes with Pre- Existing Retinal Situation Abusing Erythropoietin Doping: A Hypothesis
Current Drug Safety Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology Obstructive Sleep Apnea Syndrome: Implications in Cardiovascular Disease
Current Respiratory Medicine Reviews Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics
Current Drug Targets New Generation Calcium Channel Blockers in Hypertensive Treatment
Current Hypertension Reviews Commentary (Research Highlights: Targeted Inhibition of miR-155 Promotes Post-Stroke Neovascularization and Functional Recovery)
CNS & Neurological Disorders - Drug Targets Chronic Thromboembolic Pulmonary Hypertension
Current Respiratory Medicine Reviews The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story
Current Neuropharmacology Do Adenosine Receptors Offer New Therapeutic Options for Diabetic Nephropathy?
Current Vascular Pharmacology Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Current Vascular Pharmacology LncRNAs as Therapeutic Targets for Autophagy-involved Cardiovascular Diseases: A Review of Molecular Mechanism and T herapy Strategy
Current Medicinal Chemistry Effectors of Fatty Acid Oxidation Reduction: Promising New Anti-Ischaemic Agents
Current Pharmaceutical Design Roles of SUMOylation in Heart Development and Cardiovascular Diseases
Current Molecular Medicine ATP-Sensitive K+ Channels: Current and Putative Target for the Prevention and Treatment of Cardiovascular Diseases
Vascular Disease Prevention (Discontinued) Utilizing Delta Opioid Receptors and Peptides for Cytoprotection: Implications in Stroke and Other Neurological Disorders
CNS & Neurological Disorders - Drug Targets